After the disappointing results of everolimus in unselected patients with pretreated NSCLC (RR<5%), a phase II trial with ridaforolimus was conducted on 79 patients with pretreated KRAS mutated NSCLC, obtaining similar outcomes (RR 1%) (94). This evidence concerns the gene KRAS and non-small cell lung carcinoma.